BioLineRx (BLRX) Long-Term Debt Repayments (2023 - 2025)
Historic Long-Term Debt Repayments for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.1 million.
- BioLineRx's Long-Term Debt Repayments fell 2242.89% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.3 million, marking a year-over-year decrease of 37879.45%. This contributed to the annual value of -$14.4 million for FY2024, which is 83538.56% down from last year.
- Per BioLineRx's latest filing, its Long-Term Debt Repayments stood at -$1.1 million for Q3 2025, which was down 2242.89% from -$1.1 million recorded in Q2 2025.
- BioLineRx's Long-Term Debt Repayments' 5-year high stood at -$49000.0 during Q1 2023, with a 5-year trough of -$12.0 million in Q4 2024.
- Moreover, its 3-year median value for Long-Term Debt Repayments was -$782000.0 (2024), whereas its average is -$1.8 million.
- Per our database at Business Quant, BioLineRx's Long-Term Debt Repayments plummeted by 151565.45% in 2024 and then plummeted by 2242.89% in 2025.
- Quarter analysis of 3 years shows BioLineRx's Long-Term Debt Repayments stood at -$741000.0 in 2023, then crashed by 1515.65% to -$12.0 million in 2024, then skyrocketed by 90.65% to -$1.1 million in 2025.
- Its Long-Term Debt Repayments was -$1.1 million in Q3 2025, compared to -$1.1 million in Q2 2025 and -$1.1 million in Q1 2025.